ADC Therapeutics isn't going public in the US after all, while three other biotech IPOs bring in $319M
ADC Therapeutics is taking a last-minute U-turn at the NYSE after bumping their IPO goal up from $150 million to a potential $200 million — while three other biotechs went ahead by pricing at the midpoint or low end of their respective ranges.
Despite earlier indications that insiders would purchase $115 million worth of shares, the Lausanne, Switzerland-based company cited “adverse market conditions” for its decision to withdraw.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.